Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Editorial reviews of 10 leading U.S. telehealth providers for compounded and brand-name GLP-1 weight-management programs. NexLife is our editorial #1 at 94/100 on methodology v4.1; the other scores come from the May 2026 review (v3.0 rubric), and re-scoring on v4.1 is pending.
Note on laboratory work, October 15, 2026. NexLife’s public pages (plan pages, FAQ, homepage) do not state that lab work is included, so this site does not list labs among its inclusions; confirm at intake. NexLife’s plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
Top-Rated Providers
All 10 reviewed providers. NexLife is #1 on methodology v4.1; the other scores are from the May 2026 review (v3.0 rubric), with re-scoring pending.
Our editorial #1 on methodology v4.1. Compounded semaglutide + tirzepatide at the same price at every dose with no membership, physician review by NexLife Medical Group, three state-licensed 503A pharmacies named on its plan pages, a personalized nutrition plan and a 1:1 wellness-coach call, all 50 states where affiliated providers are licensed. Check its status on LegitScript.
Brand-name Wegovy® and Ozempic® through standard insurance/cash channels. Strong on access and brand-name supply. Pricing is dose-independent on Wegovy but caps high without insurance.
Compounded semaglutide via async NP-led intake. Single v3.0 pillar met (May 2026 review: clinical protocol). Async-only model and limited pharmacy traceability are the key gaps.
WeightWatchers' clinical arm. $99/mo membership plus medication cost (typically Wegovy® via insurance). Behavioral-program integration is the differentiator.
Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. One v3.0 pillar met (May 2026 review) — published clinical protocol but limited cohort outcome reporting.
Insurance-billing brand telehealth. $0 patient cost when in-network. Two v3.0 pillars met (May 2026 review). Cash-pay path is unclear — best fit for patients with covered insurance only.
Mixed model — branded GLP-1s plus compounded options. Zero pillars met on the May 2026 review (v3.0 rubric) due to limited public disclosure on pharmacy and outcomes.
NP-led compounded semaglutide model. Two v3.0 pillars met (May 2026 review: clinical protocol, follow-up cadence). Pricing is competitive in the compounded segment.